Cardiology Conference-CVC 2026

Cardiac sarcoidosis, though uncommon, poses significant clinical challenges when granulomatous inflammation extends to the heart. This inflammatory process may target the myocardium, the cardiac conduction system, or even the valves, frequently resulting in arrhythmias, heart block, heart failure, or in severe instances, sudden cardiac death. Patients might experience a range of symptoms—palpitations, syncope, chest discomfort, dyspnea, or persistent fatigue—though sometimes the onset is insidious.

Prompt diagnosis is critical to mitigate the risk of irreversible cardiac injury. The diagnostic workup typically incorporates advanced imaging modalities such as cardiac MRI and PET scans, alongside echocardiography. In select cases, endomyocardial biopsy remains the gold standard for confirming granulomatous infiltration.

Management strategies are multifaceted, targeting both the underlying inflammation and its cardiac sequelae. Immunosuppression, most often with corticosteroids, forms the cornerstone of therapy to limit myocardial damage. For patients at elevated risk of arrhythmias, device implantation—such as an ICD or pacemaker—may be warranted. Conventional heart failure therapies, including beta-blockers, ACE inhibitors, and diuretics, are frequently employed to support cardiac function and alleviate symptoms. Longitudinal follow-up with serial imaging and electrophysiologic assessment is essential to monitor disease progression and therapeutic response. Through early recognition, tailored immunosuppression, and judicious use of device-based interventions, clinicians can significantly improve outcomes and preserve long-term cardiac health in individuals with cardiac sarcoidosis.